NCT00499694 is a NA clinical trial of bevacizumab in Prostate Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Who is sponsoring NCT00499694?

NCT00499694 is sponsored by Barbara Ann Karmanos Cancer Institute.

What drugs are being tested in NCT00499694?

Interventions in NCT00499694: bevacizumab, satraplatin.

What condition does NCT00499694 study?

NCT00499694 studies Prostate Cancer.

Is NCT00499694 still recruiting?

NCT00499694 is currently completed. Last updated 12 May 2018.

Are results published for NCT00499694?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-05-12 · How we verify

NCT00499694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer

Completed NA Results posted Last updated 12 May 2018

What this trial tests

NA trial testing bevacizumab in Prostate Cancer in 31 participants. Completed in 1 November 2012.

Timeline

1 October 2007

Primary endpoint
1 November 2012

1 November 2012

Quick facts

Lead sponsor	Barbara Ann Karmanos Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 October 2007
Primary completion	1 November 2012
Estimated completion	1 November 2012
Sites	2 locations across United States

Drugs / interventions tested

bevacizumab (Bevacizumab-Bvzr) — full drug profile →
satraplatin — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Barbara Ann Karmanos Cancer Institute

Who can join

Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to Progression
Time frame: Every 70 days
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. TTP is measured using Kaplan-Meier product-limit.

Sponsor's own description

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as satraplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving satraplatin together with bevacizumab may kill more tumor cells. PURPOSE: This clinical trial is studying how well giving satraplatin together with bevacizumab works in treating patients with metastatic prostate cancer previously treated with docetaxel.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Yin L, Hu Q, Hartmann RW. · · 2013 · cited 35× · PMID 23880851 · DOI 10.3390/ijms140713958
Angiogenesis inhibitors in the treatment of prostate cancer.
Kluetz PG, Figg WD, Dahut WL. · · 2010 · cited 27× · PMID 20088745 · DOI 10.1517/14656560903451716
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
Gogola S, Rejzer M, Bahmad HF, Alloush F, et al · · 2023 · cited 14× · PMID 36900412 · DOI 10.3390/cancers15051621

Verify or expand the search:

Other trials of bevacizumab

Trials testing the same drug.

NCT06540326 — Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab · Phase 2 · recruiting
NCT06786026 — QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC · Phase 2 · recruiting
NCT06445062 — Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06448364 — A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination · Phase 1 · terminated
NCT06487715 — Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With · Phase 2 · unknown

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Barbara Ann Karmanos Cancer Institute trials

Trials by the same sponsor.

NCT07343297 — Ask Questions About Clinical Trials · NA · not yet recruiting
NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
NCT07098299 — Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies · Phase 1 · recruiting
NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00499694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute
Last refreshed: 12 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00499694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing